July 15, 2026, (Inside AI) — DeepSeek, the Hangzhou-based artificial intelligence model developer, has started groundwork for an initial public offering on a mainland Chinese exchange and could submit its listing application as soon as this year, according to people familiar with the matter.
The company is targeting a market debut in 2027, the sources told Bloomberg. DeepSeek is currently in discussions with accounting and banking advisers and is also seeking additional private funding ahead of the potential IPO.
The timeline remains fluid because the talks are private, the people said. DeepSeek’s move signals a new phase for China’s AI sector, where privately held firms are increasingly eyeing public markets to fuel expansion amid intensifying global competition.
DeepSeek has gained prominence for its large language models, which rival those from OpenAI and Anthropic at a fraction of the cost. Its DeepSeek-V3 model, released in late 2025, matched GPT-4 on key benchmarks while using less than $6 million in training compute, shaking up assumptions about AI development economics.
The Hangzhou-based firm has also drawn attention for its open-source strategy, releasing model weights and technical papers that have been widely adopted by researchers and enterprises. This approach has built a loyal developer community but has also raised questions about monetization—a challenge an IPO could help address.
China’s AI IPO pipeline has been thin since SenseTime’s 2021 Hong Kong listing. Regulatory tightening on data security and overseas listings has pushed more tech firms toward domestic exchanges. The Shanghai STAR Market and Shenzhen ChiNext board are likely venues for DeepSeek, given their focus on hard-tech companies.
However, mainland IPOs face strict profitability requirements and heightened scrutiny of dual-use technologies. DeepSeek’s models, while primarily civilian, have potential military applications, which could complicate approval. The company has not publicly commented on the Bloomberg report.
The Funding Race Behind the Filing #
DeepSeek’s private funding round, running parallel to IPO preparations, underscores the capital-intensive nature of foundation model development. The company has previously raised from investors including Hillhouse Capital and Sequoia China, though exact amounts remain undisclosed.
Competitors like Zhipu AI and Moonshot AI have each secured over $1 billion in 2025–2026, pushing valuations past $20 billion. DeepSeek’s leaner approach—focusing on efficiency rather than scale—has differentiated it, but public markets will demand clear revenue paths.
“DeepSeek’s efficiency narrative is compelling, but IPO investors will want to see enterprise contracts and recurring revenue, not just research breakthroughs,” said Li Wei, a Shanghai-based tech analyst at China Renaissance. “The AI model business is still largely grant-funded.”
Bloomberg’s sources did not specify the targeted raise amount or valuation. Given current private market comparables, DeepSeek could seek a valuation between $15 billion and $25 billion, though market conditions in 2027 will be decisive.
Regulatory Hurdles and Strategic Timing #
China’s Cyberspace Administration has tightened oversight of generative AI since 2023, requiring security reviews for models used by the public. DeepSeek’s open-source releases have sometimes bypassed these checks, raising compliance questions for a listed entity.
Additionally, U.S. export controls on advanced chips continue to constrain Chinese AI firms. DeepSeek has relied on older NVIDIA H800 and A100 GPUs, optimizing software to compensate. An IPO prospectus would need to detail how it mitigates supply chain risks.
The 2027 target also aligns with expectations of a more favorable market cycle. Chinese tech stocks have rebounded from 2024 lows, and AI policy support under the 14th Five-Year Plan remains strong. Still, global trade tensions could derail sentiment.
DeepSeek’s IPO would be a bellwether for China’s AI industry, testing whether homegrown foundation model companies can transition from research labs to public corporations. As the filing nears, all eyes will be on its S-1 equivalent—and the revenue numbers within.